Allscripts Healthcare Solutions, Inc. (MDRX) Reaches $15.39 After 5.00% Down Move; Shorts at Sage Therapeutics (SAGE) Raised By 12.94%

January 16, 2018 - By Clifton Ray

Sage Therapeutics Incorporated (NASDAQ:SAGE) had an increase of 12.94% in short interest. SAGE’s SI was 3.63 million shares in January as released by FINRA. Its up 12.94% from 3.22M shares previously. With 700,900 avg volume, 5 days are for Sage Therapeutics Incorporated (NASDAQ:SAGE)’s short sellers to cover SAGE’s short positions. The SI to Sage Therapeutics Incorporated’s float is 10.76%. The stock decreased 2.46% or $4.32 during the last trading session, reaching $171.54. About 216,986 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since January 16, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

The stock of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is a huge mover today! The stock decreased 4.02% or $0.65 during the last trading session, reaching $15.39. About 1.23M shares traded. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) has declined 8.32% since January 16, 2017 and is downtrending. It has underperformed by 25.02% the S&P500.The move comes after 9 months negative chart setup for the $2.78 billion company. It was reported on Jan, 16 by We have $14.62 PT which if reached, will make NASDAQ:MDRX worth $139.00 million less.

Among 26 analysts covering Allscripts-Misys Healthcare (NASDAQ:MDRX), 11 have Buy rating, 1 Sell and 14 Hold. Therefore 42% are positive. Allscripts-Misys Healthcare had 59 analyst reports since August 5, 2015 according to SRatingsIntel. Canaccord Genuity initiated the shares of MDRX in report on Wednesday, September 16 with “Buy” rating. Cantor Fitzgerald maintained Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) rating on Monday, January 8. Cantor Fitzgerald has “Buy” rating and $17.0 target. On Wednesday, March 30 the stock rating was upgraded by Morgan Stanley to “Overweight”. Maxim Group maintained it with “Buy” rating and $16 target in Tuesday, January 10 report. The company was maintained on Sunday, October 29 by RBC Capital Markets. The stock of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) has “Hold” rating given on Friday, August 4 by Oppenheimer. Morgan Stanley downgraded Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) on Tuesday, December 13 to “Underweight” rating. As per Friday, August 4, the company rating was maintained by Maxim Group. The firm has “Outperform” rating given on Monday, September 11 by Cowen & Co. Robert W. Baird maintained the stock with “Buy” rating in Tuesday, June 6 report.

Investors sentiment decreased to 1.16 in Q3 2017. Its down 0.29, from 1.45 in 2017Q2. It fall, as 22 investors sold Allscripts Healthcare Solutions, Inc. shares while 72 reduced holdings. 44 funds opened positions while 65 raised stakes. 195.75 million shares or 0.88% less from 197.48 million shares in 2017Q2 were reported. Oregon Pub Employees Retirement Fund accumulated 0.02% or 66,898 shares. Citadel Advsrs Lc reported 853,129 shares stake. Genesee Valley Trust stated it has 11,022 shares or 0.06% of all its holdings. Public Employees Retirement System Of Ohio has 0% invested in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Staley Capital Advisers holds 0.06% or 54,903 shares. Monarch Asset Management stated it has 453,080 shares or 0.62% of all its holdings. State Street Corp holds 0.01% or 5.96M shares in its portfolio. Cubist Systematic Strategies Limited Company, a Connecticut-based fund reported 30,953 shares. Parametrica Mngmt Limited stated it has 0.07% of its portfolio in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Swiss Fincl Bank holds 0% in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) or 291,400 shares. Arizona State Retirement Sys invested in 102,385 shares or 0.02% of the stock. First Interstate Bank reported 245 shares. Panagora Asset Management reported 0% of its portfolio in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). Weaver C Barksdale And Assoc Inc holds 632 shares or 0.01% of its portfolio. Great West Life Assurance Can invested in 102,577 shares or 0% of the stock.

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. The company has market cap of $2.78 billion. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. It currently has negative earnings. The companyÂ’s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services.

Analysts await Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) to report earnings on February, 15. They expect $0.13 EPS, up 30.00% or $0.03 from last year’s $0.1 per share. MDRX’s profit will be $23.48 million for 29.60 P/E if the $0.13 EPS becomes a reality. After $0.12 actual EPS reported by Allscripts Healthcare Solutions, Inc. for the previous quarter, Wall Street now forecasts 8.33% EPS growth.

Since September 14, 2017, it had 0 insider buys, and 6 selling transactions for $974,699 activity. Farley Brian sold $67,607 worth of stock or 5,000 shares. Poulton Richard J. also sold $213,840 worth of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) shares. Shares for $202,800 were sold by Black Paul.

Since December 14, 2017, it had 0 insider purchases, and 2 sales for $17.36 million activity. Robichaud Albert sold $9.57 million worth of stock. Another trade for 44,000 shares valued at $7.80 million was sold by Kanes Stephen.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.04 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.